Milestone Scientific INC

Milestone Scientific Inc. announced board director appointments and key shareholder approvals for share increases and equity plan amendments following its 2026 Annual Meeting.

Milestone Scientific Inc. announced that three of its directors have submitted notices to convert their outstanding promissory notes into common stock, contingent on the stock price reaching $0.50.

Milestone Scientific appoints two independent directors and transitions its Board Chair to Executive Chairman while restructuring founder Leonard Osser's compensation.

Milestone Scientific Inc. has announced the dismissal of CBIZ CPAs P.C. and the appointment of Grassi & Co., CPAs, P.C. as its new independent auditor.

Milestone Scientific Inc. has implemented a stock option exchange program for key executives and established a new performance-based restricted stock unit sub-plan.

Milestone Scientific Inc. has closed a $2.15 million private placement of units, consisting of common stock and warrants, to strengthen its balance sheet and fund commercial growth.

Milestone Scientific reported stable revenue for Q1 2026, with a decrease in dental sales offset by growth in medical products, while significantly reducing operating expenses.

Milestone Scientific reports continued operating losses in Q3 2025, with a 6% revenue decline driven by lower dental sales, despite re-entry into the China market.

Milestone Scientific reported a net loss of $1.48 million for Q2 2025 and $3.48 million for the six months, with a significant decrease in cash and a going concern warning, despite increased product sales.

Milestone Scientific's Q1 2025 results show stable revenue but increased operating losses due to higher expenses, with management focusing on revenue growth and cost reduction.

Milestone Scientific's Q3 2024 results show a mixed performance with increased revenue offset by continued operating losses, as the company navigates strategic shifts in distribution and product development.

Milestone Scientific's Q2 2024 results show a decrease in revenue compared to the previous year, but also a significant gain from the sale of net operating losses.

Milestone Scientific Inc. files an amendment to its 2025 annual report to include previously omitted exhibits and new certifications.

Milestone Scientific Inc. reported a net loss of $5.7 million for 2025, an improvement from 2024, but faces substantial doubt about its going concern ability and NYSE American listing compliance.

Milestone Scientific's 2024 10-K filing reveals a decrease in revenue, continued operating losses, and efforts to secure additional funding while expanding its medical product line and distribution.

Milestone Scientific modifies an executive's employment agreement regarding termination benefits and releases its annual report detailing financial performance and operational updates.

BP4 S.r.l., a 10% owner and director of Milestone Scientific Inc., reported the sale of 194,427 shares of common stock across three transactions in October 2025.

BP4 S.r.l., a director and 10% owner of Milestone Scientific Inc., reported selling 64,034 shares of common stock in late October 2025.

BP4 S.r.l., a 10% owner and director of Milestone Scientific Inc. (MLSS), reported the sale of 50,158 shares of common stock through a pre-arranged Rule 10b5-1 trading plan.

BP4 S.r.l., a 10% owner and director of Milestone Scientific Inc., reported the sale of 40,000 common shares through a pre-arranged 10b5-1 trading plan.

BP4 S.r.l., a 10% owner and director of Milestone Scientific Inc., reported selling 19,210 shares of common stock.

BP4 S.r.l., a 10% owner and director of Milestone Scientific Inc., reported the sale of 10,000 shares of common stock.

Milestone Scientific Inc. announced its 2025 Annual Meeting of Stockholders to be held virtually on December 18, 2025, to vote on director elections, an increase in authorized shares, and auditor ratification.

Milestone Scientific will hold its annual meeting of stockholders virtually on July 16, 2024, to elect directors and ratify the appointment of independent auditors.

Bp4 S.r.l., a significant shareholder in Milestone Scientific Inc., has entered voluntary liquidation, transferring sole control of its 12.35% stake to a newly appointed liquidator, Dr. Pedro Palau, who will manage the investment with a mandate to repay creditors and distribute assets.